Pharmbio Korea Inc
Pharmbio Korea Inc., a leading player in the biopharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia and beyond. Founded in 2000, the company has established itself as a pioneer in the development and manufacturing of innovative biopharmaceutical products, focusing on areas such as biosimilars and monoclonal antibodies. With a commitment to quality and cutting-edge research, Pharmbio Korea offers a range of unique services, including contract manufacturing and product development, tailored to meet the evolving needs of the healthcare sector. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. Renowned for its expertise and reliability, Pharmbio Korea continues to contribute to advancements in biomedicine, solidifying its reputation as a trusted name in the industry.
DitchCarbon Score
How does Pharmbio Korea Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmbio Korea Inc's score of 0 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmbio Korea Inc's reported carbon emissions
Pharmbio Korea Inc, headquartered in South Korea (KR), currently does not have publicly available carbon emissions data for recent years. As a result, specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions, are not disclosed. Furthermore, there are no documented reduction targets or climate pledges outlined by the company at this time. In the context of the pharmaceutical industry, many companies are increasingly committing to sustainability and carbon reduction initiatives. However, without specific commitments or data from Pharmbio Korea Inc, it is unclear how they align with these industry trends. The absence of emissions data and reduction targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmbio Korea Inc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
